Business Description
Nanogroup SA
ISIN : PLNNGRP00011
Compare
Compare
Traded in other countries / regions
NNG.Poland IPO Date
2017-12-21Description
Nanogroup SA develops biotechnological and medical projects for diagnostics, therapy and rehabilitation of oncological patients. The company's portfolio includes Nano Velos, Nano Sanguis, and Nano Thea.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 15.59 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -1.76 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -31.6 | |||||
| 3-Year EBITDA Growth Rate | 22.1 | |||||
| 3-Year EPS without NRI Growth Rate | 25.9 | |||||
| 3-Year FCF Growth Rate | 5.1 | |||||
| 3-Year Book Growth Rate | -21.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.5 | |||||
| 9-Day RSI | 60.04 | |||||
| 14-Day RSI | 60.16 | |||||
| 6-1 Month Momentum % | -1.68 | |||||
| 12-1 Month Momentum % | -20.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.09 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.68 | |||||
| Days Inventory | 133.15 | |||||
| Days Payable | 245.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | -27.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 1804.35 | |||||
| Operating Margin % | 8095.65 | |||||
| Net Margin % | 7900 | |||||
| FCF Margin % | 34495.65 | |||||
| ROE % | -26.09 | |||||
| ROA % | -9.37 | |||||
| ROIC % | -10.08 | |||||
| ROC (Joel Greenblatt) % | -382.66 | |||||
| ROCE % | -10.84 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.82 | |||||
| EV-to-EBIT | -10.56 | |||||
| EV-to-EBITDA | -10.7 | |||||
| EV-to-Revenue | -855.61 | |||||
| EV-to-FCF | -2.49 | |||||
| Earnings Yield (Greenblatt) % | -9.47 | |||||
| FCF Yield % | -38.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanogroup SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil zł) | -0.023 | ||
| EPS (TTM) (zł) | -0.522 | ||
| Beta | 1 | ||
| Volatility % | 26.18 | ||
| 14-Day RSI | 60.16 | ||
| 14-Day ATR (zł) | 0.028673 | ||
| 20-Day SMA (zł) | 1.0191 | ||
| 12-1 Month Momentum % | -20.85 | ||
| 52-Week Range (zł) | 0.85 - 1.3 | ||
| Shares Outstanding (Mil) | 20.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanogroup SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanogroup SA Stock Events
| Event | Date | Price(zł) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nanogroup SA Frequently Asked Questions
What is Nanogroup SA(WAR:NNG)'s stock price today?
The current price of WAR:NNG is zł1.03. The 52 week high of WAR:NNG is zł1.30 and 52 week low is zł0.85.
When is next earnings date of Nanogroup SA(WAR:NNG)?
The next earnings date of Nanogroup SA(WAR:NNG) is .
Does Nanogroup SA(WAR:NNG) pay dividends? If so, how much?
Nanogroup SA(WAR:NNG) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers